Amneal Pharmaceuticals, Inc.
AMRX
$11.82
-$0.37-3.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.68% | 3.24% | 5.50% | 18.40% | 13.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.68% | 3.24% | 5.50% | 18.40% | 13.29% |
| Cost of Revenue | 12.72% | -2.78% | 4.54% | 19.69% | 11.97% |
| Gross Profit | 9.99% | 14.19% | 7.19% | 16.17% | 15.52% |
| SG&A Expenses | 16.11% | 6.70% | 5.06% | 18.06% | 5.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 88.64% | -- | -5,222.00% | -- | -1,510.96% |
| Total Operating Expenses | 12.65% | 1.17% | 3.55% | 19.20% | 13.04% |
| Operating Income | 5.00% | 16.20% | 18.61% | 12.21% | 15.08% |
| Income Before Tax | -133.87% | 153.42% | 149.64% | 81.65% | -32.82% |
| Income Tax Expenses | -737.07% | 345.02% | 109.03% | -45.13% | 276.59% |
| Earnings from Continuing Operations | 54.22% | 112.13% | 130.14% | 77.78% | -53.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -32.32% | -22.24% | -24.67% | -94.89% | 22.40% |
| Net Income | 1,618.59% | 273.99% | 113.31% | 68.49% | -101.61% |
| EBIT | 5.00% | 16.20% | 18.61% | 12.21% | 15.08% |
| EBITDA | -0.30% | 13.27% | 14.56% | 13.98% | 9.97% |
| EPS Basic | 1,600.00% | 268.56% | 113.15% | 75.22% | -100.80% |
| Normalized Basic EPS | 749.32% | 10,266.67% | 310.11% | -661.54% | -3,550.00% |
| EPS Diluted | 1,600.00% | 260.82% | 113.07% | 75.22% | -100.83% |
| Normalized Diluted EPS | 728.77% | 10,000.00% | 294.38% | -661.54% | -3,550.00% |
| Average Basic Shares Outstanding | 1.46% | 1.50% | 1.23% | 27.14% | 100.78% |
| Average Diluted Shares Outstanding | 4.88% | 1.07% | 5.43% | 27.14% | 93.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |